REGN
58
2
IPG
52
2
AZO
50
4
TGNA
48
6
EFX
58
3
BAC
36
-14
FSLR
61
4
NWSA
67
2
EMC
66
4
MET
38
-6
KO
60
3
COP
51
-2
STT
50
3
RRC
75
2
SYF
92
2
AMP
69
2
QRVO
83
6
PNW
49
5
SIG
78
2
MSFT
55
-2
REGN
58
2
IPG
52
2
AZO
50
4
TGNA
48
6
EFX
58
3
BAC
36
-14
FSLR
61
4
NWSA
67
2
EMC
66
4
MET
38
-6
KO
60
3
COP
51
-2
STT
50
3
RRC
75
2
SYF
92
2
AMP
69
2
QRVO
83
6
PNW
49
5
SIG
78
2
MSFT
55
-2
Financhill
Back

ADC Therapeutics SA 10K Form

Sell
37

ADCT
ADC Therapeutics SA

Last Price:
4.56
Seasonality Move:
-28.44%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ADCT News And Ratings

See the #1 stock for the next 7 days that we like better than ADCT

ADCT Financial Statistics

Sales & Book Value

Annual Sales: $69.56M
Cash Flow: $-33.4M
Price / Cash Flow: 0
Annual Sales: $-1.80
Price / Book: 0

Profitability

EPS (TTM): -2.95000
Net Income (TTM): $-240.05M
Gross Margin: $67.03M
Return on Equity: 0%
Return on Assets: -52.47%

ADC Therapeutics SA Earnings Forecast

Key ADC Therapeutics SA Financial Ratios

  • The Gross Profit Margin over the past 5 years for ADCT is 96.36%.
  • The Selling, General & Administrative Expenses for ADCT have been equal to 152.23% of Gross Profit Margin.
  • The Research & Development expenses have been 182.76% of Revenue.
  • The Interest Expense is -19.30% of Operating Income.
  • The Net Earning history of ADCT is -345.11% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 3 years.

ADC Therapeutics SA Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biotechnology
Sector: Health Care
Current Symbol: ADCT
CUSIP: H0036K
Website: adctherapeutics.com

Debt

Debt-to-Equity Ratio: -0.76
Current Ratio: 4.97
Quick Ratio: 4.49

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ADCT Technical Analysis vs Fundamental Analysis

Sell
37
ADC Therapeutics SA (ADCT) is a Sell

Is ADC Therapeutics SA a Buy or a Sell?